Dr. David M. Gershenson, MD
- Medicare services, 2024
- 71
- Medicare patients, 2024
- 38
- Part D claims, 2024
- 14
- Publications
- 402
- Clinical trials
- 10
- Practice address
- 1515 Holcombe Blvd, Houston, TX 77030
- Professional email
- Get professional email
- Personal email
- Get personal email
- Mobile number
- Get mobile number
Primary practice
Find Dr. Gershenson's professional email, personal email and mobile number
Dmand AI checks each channel through healthcare-specific waterfall enrichment. See what is on file with a free account, with practice phones, licenses and affiliations.
Dr. David M. Gershenson is a gynecologic oncologist in Houston, Texas
Dr. Gershenson practices at The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System.
Dr. Gershenson's NPI, 1477651099, was assigned on September 20, 2006. Dr. Gershenson graduated from Vanderbilt University School Of Medicine in 1971. Dr. Gershenson holds Texas license F4835.
- NPI
- 1477651099NPI Registry (opens in a new tab)
- Medicare PAC ID
- 8325059009
- NPI enumeration date
- September 20, 2006
- NPI status
- Active
- Accepts Medicare assignment
- Yes
- Offers telehealth
- Yes
- Professional email
- Get email
- Personal email
- Get email
- Mobile number
- Get number
- Sex
- Male
- Estimated age
- 81
- Medical school graduation
- 1971
Sources: NPPES NPI Registry (CMS); Dmand AI Professional Profile Data; Dmand AI Affiliation Data; and Doctors and Clinicians National Downloadable File (CMS)
Dr. David M. Gershenson practices at The University of Texas MD Anderson Cancer Center in Houston, Texas
Dr. Gershenson's primary practice is The University of Texas MD Anderson Cancer Center, at 1515 Holcombe Blvd, Houston, TX 77030.
- The University of Texas MD Anderson Cancer Center1515 Holcombe Blvd, Houston, TX 77030
Source: Dmand AI Affiliation Data
Dr. David M. Gershenson is affiliated with 1 site of care and 1 medical group
Dr. Gershenson's primary practice is The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System. The medical group on file is Physicians Referral Service.
Sources: Dmand AI Affiliation Data; and Dmand AI Org Hierarchy Data
Dmand AI tracks the EHR system at Dr. David M. Gershenson's practice
Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Gershenson practices. Vendor and product names are available with a free account.
| Site | EHR vendor and product |
|---|---|
| The University of Texas MD Anderson Cancer Center | Available with a free account |
Source: Dmand AI Technology Install Data
For health IT teams
Dmand AI maps EHR vendors, IT decision makers and buying committees across The University of Texas System and 6.2K+ hospitals, with verified contacts in the same login.
Dr. David M. Gershenson is one of 131 gynecologic oncologists in Texas
Gynecologic oncology is Dr. Gershenson's primary specialty in the NPI Registry, under taxonomy code 207VX0201X. Dr. Gershenson is board certified in gynecologic oncology by the American Board of Obstetrics and Gynecology. Dmand AI has Dr. Gershenson's licenses on file in 10 states: Texas, Florida, Georgia, Arizona, Louisiana, Oklahoma, Tennessee, Washington, Alabama and Mississippi.
Specialties and state licenses
- Gynecologic oncology, TexasPrimary
- Florida license
- Georgia license
- Arizona license
- Louisiana license
- Oklahoma license
- Tennessee license
- Washington license
- Alabama license
- Mississippi license
Gynecologic oncologists near Dr. Gershenson
Counts of gynecologic oncologists with a Dmand AI profile, by place and practice. Each opens the list.
Sources: NPPES NPI Registry (CMS); Dmand AI Professional Profile Data; and Dmand AI Peer Benchmarks
Dr. David M. Gershenson billed Medicare for 71 services in 2024
CMS data shows 71 Medicare services from Dr. Gershenson across 2 procedure codes in 2024, all of them office visits, for 38 Medicare patients. Medicare paid $5,921 for them. Every service was in a facility, such as a hospital, rather than an office.
Dr. Gershenson's Medicare services by type, 2023 to 2024
- 2023
- 2024
- Office and hospital visits
- 2023: 962024: 7126%
Dr. Gershenson compared with the Texas median for gynecologic oncologists, 2024
- Dr. Gershenson
- Texas median
- Medicare services
- 71vs 22468% below
- Medicare patients
- 38vs 10564% below
Medians across 129 gynecologic oncologists in Texas with Dmand AI profiles that report each measure.
Dr. Gershenson's most billed Medicare procedure codes, 2024
CMS publishes codes billed for 11 or more Medicare patients. Each label is the code family; CPT descriptions are licensed by the AMA.
Need commercial claims for Dr. Gershenson?
Medicare shows one payer. Book a meeting to get commercial claims data for Dr. Gershenson and other gynecologic oncologists in Texas.
Sources: Medicare Physician & Other Practitioners - by Provider and Service (CMS), 2024 data; and Dmand AI Peer Benchmarks
Dr. David M. Gershenson treated 38 Medicare patients in 2024, average age 70
CMS counts 38 Medicare patients who saw Dr. Gershenson in 2024. The largest group is 65 to 74, with 25 patients. 63% of them have high blood pressure, and 58% have high cholesterol. Their average risk score is 2.45, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.
Across all payers, Dmand AI patient panel data puts Dr. Gershenson's median patient age at 65, with 100% women.
Dr. Gershenson's Medicare patients by age, 2024
CMS leaves out age groups with fewer than 11 patients.
Chronic conditions among Dr. Gershenson's Medicare patients, 2024
- High blood pressure63%
- High cholesterol58%
- Anxiety42%
- Mood disorders39%
- Depression32%
- Arthritis29%
- Cancer29%
Share of Medicare patients with each condition. A patient can have several.
Dr. Gershenson's patients across all payers
Dmand AI patient panel data covers Medicare, Medicaid and commercial patients.
Patient panel by age, all payers
Median age 65
Patient panel by sex, all payers
- Women100%
- Men0%
Sources: Dmand AI Patient Panel Data; and Medicare Physician & Other Practitioners - by Provider (CMS), 2024 data
Dr. David M. Gershenson wrote 14 Medicare Part D claims in 2024
In 2024, Dr. Gershenson wrote 14 Medicare Part D claims.
Source: Medicare Part D Prescribers - by Provider (CMS), 2024 data
Dr. David M. Gershenson scored 84 out of 100 in Medicare's MIPS program for 2024
CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Gershenson for performance year 2024, reported as part of a group. Dr. Gershenson accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Gershenson as offering telehealth.
- Accepts Medicare assignment
- Yes
- Offers telehealth
- Yes
Dr. Gershenson's MIPS scores, performance year 2024
- 84of 100Final score
- 70.8of 100Quality
- 100of 100Promoting Interoperability
- 40of 100Improvement Activities
- 68of 100Cost
Each score is out of 100. The final score weighs the categories CMS scored for this clinician.
Sources: Doctors and Clinicians National Downloadable File (CMS); and Clinician Public Reporting: Overall MIPS Performance (CMS), 2024 data, released September 10, 2026
For MedTech and pharma teams
Filter 7.4M+ HCPs by Medicare procedures, Part D drugs and Open Payments history, then reach them with verified contacts in one login.
Dr. David M. Gershenson has 402 publications on record
Dmand AI links 402 papers to Dr. Gershenson, published from 2005 to 2025. 2020 was the busiest year, with 15. The most frequent topics are Ovarian Neoplasms, Antineoplastic Combined Chemotherapy Protocols and Cystadenocarcinoma, Serous. Dr. Gershenson has published most often in Gynecol Oncol. Dr. Gershenson's most frequent co-authors are Anil K. Sood, MD, Thomas W. Burke, MD and Charles F. Levenback, MD.
Dr. Gershenson's papers by year, 2016 to 2025
Topics Dr. Gershenson writes about most
- Ovarian Neoplasms
- Antineoplastic Combined Chemotherapy Protocols
- Cystadenocarcinoma, Serous
- Cisplatin
- Antineoplastic Agents
- Carcinoma
- Cell Line, Tumor
- Peritoneal Neoplasms
Dr. Gershenson's most frequent co-authors
- Anil K. Sood, MD56 shared papers
- Thomas W. Burke, MD52 shared papers
- Charles F. Levenback, MD44 shared papers
Recent publications by Dr. Gershenson
Int J Gynecol Cancer
Int J Gynecol Cancer
Am J Obstet Gynecol
See who Dr. Gershenson researches with
Physician Network Discovery turns co-authorship, shared hospitals and shared groups into a map of who Dr. Gershenson works with, so you can find a warm path to the right gynecologic oncologists.
Sources: PubMed (National Library of Medicine); and Dmand AI Research Linkage
Dr. David M. Gershenson has worked on 10 clinical trials
Dmand AI links Dr. Gershenson to 10 clinical trials, 3 of them phase 2 studies. 3 are still active or recruiting. Conditions studied include Ovarian Neoplasms, Carcinoma, Ovarian Epithelial and Cystadenocarcinoma. M.D. Anderson Cancer Center sponsors the most, 4.
Clinical trials with Dr. Gershenson by phase
- NonePhase 1: no trials
- 1Phase 1/2: 1 trial
- 3Phase 2: 3 trials
- 1Phase 2/3: 1 trial
- 1Phase 3: 1 trial
- NonePhase 4: no trials
Conditions in Dr. Gershenson's trials
- Ovarian Neoplasms
- Carcinoma, Ovarian Epithelial
- Cystadenocarcinoma
- Fallopian Tube Diseases
- Cystadenocarcinoma, Serous
Investigators on the most trials with Dr. Gershenson
- Deborah K. Armstrong, MD1 shared trial
- Jack B. Basil, MD1 shared trial
- Jubilee Brown, MD1 shared trial
Recent clinical trials with Dr. Gershenson
Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer (opens in a new tab)
Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer (opens in a new tab)
Bevacizumab in Treating Patients With Recurrent Sex Cord-Stromal Tumors of the Ovary (opens in a new tab)
Selumetinib Sulfate in Treating Woman With Recurrent Low-Grade Ovarian Cancer or Peritoneum Cancer (opens in a new tab)
Data Collection for Patients With Low Grade Ovarian or Peritoneal Tumors (opens in a new tab)
Sources: Dmand AI Research Linkage; and ClinicalTrials.gov (National Library of Medicine)
Dr. David M. Gershenson received $7,999 in industry payments from 2016 to 2022
CMS Open Payments shows 18 general payments to Dr. Gershenson from 6 drug and device companies from 2016 to 2022. Consulting fees make up the largest share, 60% of the total. Genentech, Inc. paid the most, $3,655. It also lists 7 research payments totaling $1,854 from 2023 to 2025.
General payments to Dr. Gershenson by program year, 2016 to 2022
General payments to Dr. Gershenson by kind, 2016 to 2022
- Consulting fees$4,80060%
- Honoraria$2,20028%
- Food and beverage$93012%
- Education$681%
Companies that paid Dr. Gershenson the most, 2016 to 2022
Share is of all general payments to this clinician.
Source: Open Payments (CMS), 2025 data, released July 7, 2026
Dr. David M. Gershenson has 6 awards and honors on record
Dmand AI lists 6 awards for Dr. Gershenson, most recently America's Top Doctors in 2014.
Awards and honors for Dr. Gershenson
- 2014
- America's Top Doctors
- 2013
- America's Top Doctors for Cancer
- Top Doctors:SE Texas
- Undated
- ACOG Fellow
- ACS Fellow
- Super Doc
Source: Dmand AI Professional Profile Data
Dr. David M. Gershenson graduated from Vanderbilt University School Of Medicine
Dr. Gershenson graduated from Vanderbilt University School Of Medicine in 1971. Dr. Gershenson is a member of American College of Obstetricians and Gynecologists, ACS and ASCO.
- Medical school
- Board certified in gynecologic oncology
- Board certified in obstetrics & gynecology
Source: Dmand AI Professional Profile Data
Dr. David M. Gershenson accepts plans from 7 insurance carriers
Dr. Gershenson is in network with 7 carriers, including Aetna, Excellus BlueCross BlueShield and United Healthcare. PPO plans come from the most carriers, 5. Check the plan with the practice before a visit.
- Aetna
- Excellus BlueCross BlueShield
- United Healthcare
- Blue Cross Blue Shield of Michigan
- Blue Cross and Blue Shield of Kansas City
- Cigna
- CMS Medicare
Plan types Dr. Gershenson accepts, by number of carriers
- PPO5
- HMO4
- Medicare4
- POS4
- EPO3
Source: Dmand AI Insurance Network Data
Sources for Dr. David M. Gershenson's profile data
| Data on this page | Source |
|---|---|
| NPI, name, sex, specialty and licenses | NPPES NPI Registry (CMS) (opens in a new tab)Dmand AI Professional Profile Data |
| Practice locations and phone | Dmand AI Affiliation Data |
| Primary practice, affiliations and health system | Dmand AI Affiliation DataDmand AI Org Hierarchy Data |
| Medicare services and procedure codes | Medicare Physician & Other Practitioners - by Provider and Service (CMS) (opens in a new tab) |
| State medians for the same specialty | Dmand AI Peer Benchmarks |
| Medicare patients and the all-payer patient panel | Dmand AI Patient Panel DataMedicare Physician & Other Practitioners - by Provider (CMS) (opens in a new tab) |
| Part D prescribing | Medicare Part D Prescribers - by Provider (CMS) (opens in a new tab) |
| MIPS scores, telehealth, assignment and procedure percentiles | Doctors and Clinicians National Downloadable File (CMS) (opens in a new tab)Clinician Public Reporting: Overall MIPS Performance (CMS) (opens in a new tab) |
| Publications, topics and co-authors | PubMed (National Library of Medicine) (opens in a new tab)Dmand AI Research Linkage |
| Clinical trials and co-investigators | Dmand AI Research LinkageClinicalTrials.gov (National Library of Medicine) (opens in a new tab) |
| Industry payments | Open Payments (CMS) (opens in a new tab) |
| Awards and committee roles | Dmand AI Professional Profile Data |
| Training, board certification and memberships | Dmand AI Professional Profile Data |
| Insurance carriers and plan types | Dmand AI Insurance Network Data |
| EHR at each practice site | Dmand AI Technology Install Data |
| Similar physicians | Dmand AI Affiliation Data |
Data last refreshed October 2026Report an inaccuracyRemove my information
FAQ
Frequently asked questions about Dr. David M. Gershenson
Spotted something out of date? Email hello@dmand.ai and we will check the record. Contact details live in the free trial.
What is Dr. David M. Gershenson's NPI number?
Dr. David M. Gershenson's NPI number is 1477651099. It was assigned on September 20, 2006, and it is active in the NPI Registry.
What kind of doctor is Dr. David M. Gershenson?
Dr. David M. Gershenson is a gynecologic oncologist in Houston, Texas. The primary specialty in the NPI Registry is Gynecologic Oncology Physician (taxonomy code 207VX0201X).
Where does Dr. David M. Gershenson practice?
Dr. Gershenson practices at 1515 Holcombe Blvd, Houston, TX 77030. Dr. Gershenson's primary practice is The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System.
What is Dr. David M. Gershenson's medical license number?
Dr. Gershenson holds Texas license F4835, one of the licenses on file in 10 states.
Which states has Dr. David M. Gershenson been licensed in?
Dmand AI has state licenses on file for Dr. Gershenson in Texas (1979 to 2027), Florida (since 2021), Georgia (2023 to 2027), Arizona (2023 to 2026), Louisiana (2023 to 2026), Oklahoma (2020 to 2026), Tennessee (2023 to 2026), Washington (2023 to 2026), Alabama (2023 to 2025) and Mississippi (2023 to 2025).
Which hospitals is Dr. David M. Gershenson affiliated with?
Dr. Gershenson practices at The University of Texas MD Anderson Cancer Center in Houston, Texas.
What medical group is Dr. David M. Gershenson part of?
Dr. Gershenson is linked to Physicians Referral Service.
Does Dr. David M. Gershenson accept Medicare?
Yes. CMS data shows Dr. Gershenson billed Medicare for 71 services in 2024, and Dr. Gershenson accepts Medicare assignment.
Does Dr. David M. Gershenson offer telehealth?
Yes. The CMS Doctors and Clinicians file lists Dr. Gershenson as offering telehealth services.
What is Dr. David M. Gershenson's MIPS score?
Dr. Gershenson's MIPS final score for performance year 2024 is 84 out of 100, reported as part of a group.
Show 9 more questionsShow fewer questions
How many Medicare patients does Dr. David M. Gershenson see?
CMS counts 38 Medicare patients who saw Dr. Gershenson in 2024, with an average age of 70.
Is Dr. David M. Gershenson board certified?
Yes. Dr. Gershenson is board certified in gynecologic oncology by the American Board of Obstetrics and Gynecology.
What services does Dr. David M. Gershenson bill to Medicare?
In 2024, Dr. Gershenson's most billed Medicare services were office visit, established patient (99214) and office visit, new patient (99205).
Where did Dr. David M. Gershenson go to medical school?
Dr. Gershenson graduated from Vanderbilt University School Of Medicine in 1971.
Has Dr. David M. Gershenson received payments from drug or device companies?
CMS Open Payments shows $7,999 in general payments to Dr. Gershenson from 6 companies from 2016 to 2022. The largest total came from Genentech, Inc.
How long has Dr. David M. Gershenson been practicing?
Dr. Gershenson graduated from medical school in 1971, 55 years ago.
Does Dr. David M. Gershenson do research?
Dmand AI links 402 publications to Dr. Gershenson, published from 2005 to 2025. Dr. Gershenson has worked on 10 clinical trials.
Who does Dr. David M. Gershenson publish with?
Dr. Gershenson's most frequent co-authors are Anil K. Sood, MD (56 shared papers), Thomas W. Burke, MD (52 shared papers) and Charles F. Levenback, MD (44 shared papers).
What insurance does Dr. David M. Gershenson accept?
Dr. Gershenson is in network with 7 carriers, including Aetna, Excellus BlueCross BlueShield and United Healthcare. PPO plans come from the most carriers, 5. Check the plan with the practice before a visit.
Selling to gynecologic oncology practices?
See gynecologic oncologists in Texas by site of care and group
Find the practices, groups and hospitals they work with, and the right people to contact at each.
- 30 days free
- Self-serve
- No credit card